LONG-TERM FOLLOW-UP OF A CHOP-BASED REGIMEN WITH MAINTENANCE THERAPY AND CENTRAL-NERVOUS-SYSTEM PROPHYLAXIS IN LYMPHOBLASTIC NON-HODGKINS-LYMPHOMA

被引：30

作者：

COLGAN, JP ^{[1
]}

ANDERSEN, J ^{[1
]}

HABERMANN, TM ^{[1
]}

EARLE, JD ^{[1
]}

OCONNELL, MJ ^{[1
]}

NEIMAN, RS ^{[1
]}

MANN, RB ^{[1
]}

GLICK, JH ^{[1
]}

机构：

[1] MAYO CLIN & MAYO FDN,DIV HEMATOL & INTERNAL MED,ROCHESTER,MN 55905

来源：

LEUKEMIA & LYMPHOMA | 1994年 / 15卷 / 3-4期

关键词：

CHOP L-ASPARAGINASE REGIMEN; CNS PROPHYLAXIS; LYMPHOBLASTIC; NON-HODGKINS LYMPHOMA; PHASE II TRIAL;

D O I：

10.3109/10428199409049726

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial in adult patients with lymphoblastic non-Hodgkin's lymphoma. Thirty-nine patients with no central nervous system (CNS) involvement were treated with an induction cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)/L-asparaginase regimen and CNS prophylaxis that included intrathecally administered methotrexate given 6 times and 24 Gy midplane cranial radiation in 12 fractions. Thirty-one patients (79%) achieved a complete remission (CR). Of the 31 patients with CRs, 12 relapsed (39%). CNS relapse occurred in three patients. All patients who entered a CR were treated with maintenance CHOP, cytosine arabinoside (Ara-C), and methotrexate and subsequently with Ara-C and methotrexate. Life-threatening leukopenia or thrombocytopenia was experienced in 69% of patients in the induction phase and in 70% in the maintenance phase. Nineteen of 39 patients (49%) remain in CR with a followup to 9 years. Bone marrow involvement was associated with a significantly worse survival (P = 0.03).

引用

页码：291 / 296

页数：6

共 20 条

[1]

National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage, Cancer, 49, pp. 2112-2135, (1982)

[2]

Kung P.C., Long J.C., McCaffrey R.P., Ratliff R.L., Harrison T.A., Baltimore D., Terminal deoxynucleotidyl transferase in the diagnosis of leukemia and malignant lymphoma, Am. J. Med., 64, pp. 788-794, (1978)

[3]

Donlon J.A., Jaffe E.S., Braylan R.C., Terminal deoxynucleotidyl transferase activity in malignant lymphomas, New Engl. J. Med., 297, pp. 461-464, (1977)

[4]

Rosen P.J., Feinstein D.I., Pattengale P.K., Tindle B.H., Williams A.H., Cain M.J., Bonorris J.B., Parker J.W., Lukes R.J., Convoluted lymphocytic lymphoma in adults: A clinicopathologic entity, Ann. Intern. Med., 89, pp. 319-324, (1978)

[5]

Nathwani B.N., Diamond L.W., Winberg C.D., Kim H., Bearman R.M., Glick J.H., Jones S.E., Gams R.A., Nissen N.I., Rappaport H., Lymphoblastic lymphoma: A clinicopathologic study of 95 patients, Cancer, 48, pp. 2347-2357, (1981)

[6]

Streuli R.A., Kaneko Y., Variakojis D., Kinnealey A., Golomb H.M., Rowley J.D., Lymphoblastic lymphoma in adults, Cancer, 47, pp. 2510-2516, (1981)

[7]

Voakes J.B., Jones S.E., McKelvey E.M., The chemotherapy of lymphoblastic lymphoma, Blood, 57, pp. 186-188, (1981)

[8]

Coleman C.N., Cohen J.R., Burke J.S., Rosenberg S.A., Lymphoblastic lymphoma in adults: results of a pilot protocol, Blood, 57, pp. 679-684, (1981)

[9]

Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M., Report of the Committee on Hodgkin's Disease Staging Classification, Cancer Res., 31, pp. 1860-1861, (1971)

[10]

Peterson B.A., Bloomfield C.D., Prolonged maintained remissions of adult acute non-lymphocytic leukaemia, Lancet, 2, pp. 158-160, (1977)

← 1 2 →